Cargando…
Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients. PAH may be idiopathic in nature or associated...
Autores principales: | Mirza, Shireen, Foley, Raymond J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412595/ https://www.ncbi.nlm.nih.gov/pubmed/22872790 http://dx.doi.org/10.4137/CCRPM.S8678 |
Ejemplares similares
-
Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review
por: Buckley, Mitchell S, et al.
Publicado: (2014) -
Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013) -
Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010) -
Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008) -
Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
por: Pugliese, Steven C, et al.
Publicado: (2016)